title: Acute myocardial infarction.
abstract: Acute myocardial infarction has traditionally been divided into ST elevation or non-ST elevation myocardial infarction; however, therapies are similar between the two, and the overall management of acute myocardial infarction can be reviewed for simplicity. Acute myocardial infarction remains a leading cause of morbidity and mortality worldwide, despite substantial improvements in prognosis over the past decade. The progress is a result of several major trends, including improvements in risk stratification, more widespread use of an invasive strategy, implementation of care delivery systems prioritising immediate revascularisation through percutaneous coronary intervention (or fibrinolysis), advances in antiplatelet agents and anticoagulants, and greater use of secondary prevention strategies such as statins. This seminar discusses the important topics of the pathophysiology, epidemiological trends, and modern management of acute myocardial infarction, focusing on the recent advances in reperfusion strategies and pharmacological treatment approaches.
authors: Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
authors: Grant W
authors: GW
authors: Reed
authors: Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
authors: Jeffrey E
authors: JE
authors: Rossi
authors: Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Executive Director Cardiometabolic Trials, Harvard Clinical Research Institute, Boston, MA, USA. Electronic address: christopher.cannon@hcri.harvard.edu.
authors: Christopher P
authors: CP
authors: Cannon
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology*; D015425:Myocardial Reperfusion / Q000379:methods* / Q000639:trends; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D018570:Risk Assessment; D015912:Thrombolytic Therapy
chemical_list: D000925:Anticoagulants; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors